

1

2

**Title: Aggregated eosinophils characterize airway mucus properties**

3

4

**Authors:** Yui Miyabe<sup>1,2</sup>, Mineyo Fukuchi<sup>1</sup>, Hiroki Tomizawa<sup>1,2</sup>, Yuka Nakamura<sup>1</sup>, Mitsutoshi

5

Jikei<sup>3</sup>, Yoshinori Matsuwaki<sup>4</sup>, Misaki Arima<sup>1</sup>, Yasunori Konno<sup>1</sup>, Yuki Moritoki<sup>1</sup>, Masahide

6

Takeda<sup>1</sup>, Naoya Tanabe<sup>5</sup>, Hiroshi Sima<sup>5</sup>, Yusuke Shiraishi<sup>5</sup>, Toyohiro Hirai<sup>5</sup>, Nobuo Ohta<sup>6</sup>,

7

Junko Takahata<sup>7</sup>, Atsushi Matsubara<sup>7</sup>, Takechiyo Yamada<sup>2</sup>, Koichiro Asano<sup>8</sup>, Isao Miyairi<sup>9</sup>,

8

Rossana C. N. Melo<sup>10</sup>, Peter F. Weller<sup>11</sup>, and Shigeharu Ueki<sup>1\*</sup>

9

**Affiliations:**

10

<sup>1</sup>Department of General Internal Medicine and Clinical Laboratory Medicine, Akita

11

University Graduate School of Medicine; Akita, Akita 010-8543, Japan.

12

<sup>2</sup>Department of Otorhinolaryngology Head and Neck Surgery, Akita University Graduate

13

School of Medicine; Akita, Akita 010-8543, Japan.

14

<sup>3</sup>Department of Materials Science, Akita University Graduate School of Engineering

15

Science; Akita, Akita 010-8502, Japan.

16

<sup>4</sup>Matsuwaki Clinic Shinagawa; Shinagawa, Tokyo 141-0001, Japan.

17

<sup>5</sup>Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University;

18

Kyoto, Kyoto 606-8501, Japan.

19

<sup>6</sup>Department of Otolaryngology, Tohoku Medical and Pharmaceutical University; Sendai,

20

Miyagi 981-8558, Japan.

21           <sup>7</sup> Department of Otorhinolaryngology-Head and Neck Surgery, Hirosaki University  
22 Graduate School of Medicine; Hirosaki, Aomori 036-8562, Japan.

23           <sup>8</sup>Division of Pulmonary Medicine, Department of Medicine, Tokai University School of  
24 Medicine; Isehara, Kanagawa 259-1193, Japan.

25           <sup>9</sup>Department of Pediatrics, Hamamatsu University School of Medicine; Hamamatsu,  
26 Shizuoka 431-3192, Japan.

27           <sup>10</sup>Laboratory of Cellular Biology, Department of Biology, Institute of Biological Sciences,  
28 Federal University of Juiz de Fora, Juiz de Fora Campus; MG, 36036-900, Brazil.

29           <sup>11</sup>Divisions of Allergy and Inflammation and Infectious Diseases, Department of  
30 Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, 02215,  
31 USA.

32

33 \*Corresponding author. Shigeharu Ueki, MD, PhD, Department of General Internal Medicine and  
34 Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita  
35 010-8543, Japan

36 Phone: +81-18-884-6209; Fax: +81-18-884-6209

37 Email: shigeh@hos.akita-u.ac.jp

38

39 **One Sentence Summary:** Intraluminal accumulation and activation of eosinophils contribute to  
40 the clinical properties of airway mucus and may serve as a therapeutic target.

41 **Abstract:** Uncontrolled airway mucus is associated with diverse diseases. We hypothesized that  
42 the physical characteristics of infiltrating granulocytes themselves affect the clinical properties of

43 mucus. Surgically obtained nasal mucus from patients with eosinophilic chronic rhinosinusitis  
44 (ECRS) and neutrophil-dominant non-eosinophilic chronic rhinosinusitis (non-ECRS) was  
45 assessed in terms of computed tomography (CT) density, viscosity, water content, wettability, and  
46 granulocyte-specific proteins. In an observational study, we found that nasal mucus from patients  
47 with ECRS had significantly higher CT density, viscosity, dry weight, and hydrophobicity than  
48 mucus from patients with non-ECRS. The levels of eosinophil-specific proteins in nasal mucus  
49 correlated with its physical properties. When isolated human eosinophils and neutrophils were  
50 stimulated to induce extracellular traps followed by aggregate formation, we found that cell  
51 aggregates showed physical and pathological findings that closely resembled mucus. Co-treatment  
52 with heparin (which slenderizes the structure of eosinophil extracellular traps) and DNase  
53 efficiently induced a reduction in the viscosity and hydrophobicity of both eosinophil aggregates  
54 and eosinophilic mucus. The present study highlights the pathogenesis of mucus stasis in  
55 infiltrated granulocyte aggregates from a new perspective. The combination of DNase and heparin  
56 might be a novel therapeutic modality against pathologic viscous eosinophilic mucus.

57

58 **Main Text:**

## 59 **INTRODUCTION**

60 Airway mucus has a role as a physical barrier to prevent the entry of external pathogens  
61 and contributes to the expulsion of foreign substances through mucociliary transport and  
62 maintenance of local humidity (1). However, abnormal production, hypercondensation, and  
63 decreased clearance of airway mucus can lead to airway obstruction and prolonged inflammation,  
64 thereby leading to a poor prognosis (2).

65           In bacterial infection, airway mucus contains abundant neutrophils that migrate into the  
66 airways to eliminate pathogens through phagocytosis. These neutrophils also possess  
67 anti-microbial capacity in the form of the release of sticky chromatin structures, i.e., neutrophil  
68 extracellular traps (NETs). NETs serve as scaffolding for antimicrobial mediators such as histones  
69 and granule proteins, and contribute to the entrapment of bacteria and other extracellular  
70 pathogens (3). Abundant eosinophil extracellular traps (EETs) were also observed in patients with  
71 diverse eosinophilic diseases (4, 5). These extracellular traps (ETs) are major components of  
72 inflammatory cell-rich mucus, and contribute to its viscosity.

73           Interestingly, a clinical characteristic of eosinophil-dominant mucus, which is often  
74 associated with type 2 inflammation, is that it shows high viscosity. For instance, eosinophilic  
75 chronic rhinosinusitis (ECRS) is resistant to conservative treatments using antimicrobial therapies  
76 or nebulizers, and frequently requires surgical intervention for mucus removal, which is in contrast  
77 to infectious rhinosinusitis (6, 7). Luminal impaction due to viscous mucus is also observed in  
78 other eosinophilic upper and lower airway diseases such as eosinophilic otitis media (5), allergic  
79 fungal sinusitis (8), allergic bronchopulmonary aspergillosis (9-11), plastic bronchitis (12, 13),  
80 and eosinophilic asthma (14-16). Eosinophilic airway mucus has been clinically recognized as  
81 allergic mucin, eosinophilic mucin, and mucus plug, and its consistency has been described as  
82 being like chewing gum, cottage cheese, axle grease, and peanut butter, which can be a clue to the  
83 diagnosis (17-19). The clinical similarity of eosinophil-rich mucus in different airway diseases has  
84 been previously discussed (20), although the precise mechanisms leading to its accumulation are  
85 less well understood.

86           It is of paramount importance to elucidate the mechanisms and appropriate control of  
87 mucus in muco-obstructive airway diseases. The objective of this study was to clarify the

88 contribution of granulocytes to the characteristics of pathological mucus. Using multiple  
89 modalities including biophysical approaches, our results highlight the differences between  
90 neutrophil- and eosinophil-rich mucus, and the contributions of aggregated extracellular  
91 trap-producing granulocytes.

92

## 93 **RESULTS**

### 94 **Eosinophilic mucus shows high CT density**

95         Microscopically, mucus from patients with ECRS is characterized by the presence of  
96 abundant eosinophil accumulations, whereas that from non-ECRS patients is characterized by  
97 neutrophil accumulations (**Fig. 1A**). First, we questioned whether, in addition to differences in  
98 cellular composition, mucus density would also vary between ECRS and non-ECRS patients. In  
99 typical eosinophilic mucus, a unique radiological imaging presentation is high attenuation on  
100 computed tomography (CT) (10, 21). Accordingly, as shown in **Fig. 1B**, the mucus in patients with  
101 ECRS often shows a high CT attenuation area, unlike that in non-ECRS patients. Surgically  
102 obtained mucus was hyperconcentrated as shown by macroscopic images in **Fig. 1C** and **Movie**  
103 **S1**. Mucus collected from patients with ECRS was typically highly viscoelastic and thicker than  
104 that from patients with non-ECRS. We initially aimed to quantify the CT value of mucus on  
105 routine sinus CT imaging; however, mucosal thickening and mucus were indistinguishable. To  
106 solve this problem, we conducted an observational study to collect mucus samples from patients  
107 with ECRS and non-ECRS who needed surgical treatment, and established *ex-vivo* CT imaging  
108 (**Fig. 1D**, **Fig. S1**). The patient demographics are indicated in **Table S1**. As expected, the mean CT  
109 value of mucus from patients with ECRS showed significantly higher x-ray attenuation than  
110 mucus from patients with non-ECRS ( $48.5 \pm 16.9$  Hounsfield units [HU] vs  $34.2 \pm 6.9$  HU,

111  $p < 0.01$ , **Fig. 1D**). These results indicate the presence of radiographical differences between  
112 eosinophil- and neutrophil-dominant mucus.

113

#### 114 **Biophysical properties of mucus are associated with its CT density**

115 Next, we assessed the rheological properties of mucus samples, measuring their shear  
116 viscosity using a rotational viscometer (**Fig. 2A**). With the plate in contact with the mucus sample,  
117 the shear viscosity was measured at different values of shear stress. As shown in **Fig. 2B**, the  
118 mucus viscosity decreased when the shear rate increased, indicating a non-Newtonian  
119 shear-thinning pattern, as found in previous studies on airway mucus (22). As expected, higher  
120 shear viscosities were obtained in the mucus from patients with ECRS than in that obtained from  
121 patients with non-ECRS. A positive correlation between viscosity and CT values was also  
122 observed (**Fig. 2C**). Next, we assessed the dry weight of the mucus using a thermogravimetric  
123 analyzer (TGA) (**Fig. 2D**). The weight reduction of ECRS mucus took a longer time than  
124 non-ECRS mucus to reach a plateau when the mucus samples were concentrated by gradually  
125 heating up to 100°C (**Fig. 2E**), indicating a higher polymer concentration. In a randomly selected  
126 sample (because of technical limitations) that we tested, the dry weight of mucus from patients  
127 with ECRS was significantly higher than that of patients with non-ECRS ( $40.6 \pm 7.0\%$  vs  $19.4 \pm$   
128  $6.2\%$ ,  $p < 0.01$ ), and positively correlated with the CT value (**Fig. 2F**). To further determine the  
129 wettability of the mucus, the air-dried mucus surface was analyzed with a static water contact  
130 angle (**Fig. 2G**). The mucus from patients with ECRS showed significantly higher hydrophobicity  
131 than that from patients with non-ECRS ( $75.5 \pm 18.3^\circ$  vs  $44.9 \pm 18.6^\circ$ ,  $p < 0.0001$ , **Fig. 2H**). The  
132 mucus-water contact angles and CT values were positively correlated (**Fig. 2I**). These results

133 indicated that the biophysical properties of the mucus were associated with its radiographical  
134 findings.

135

### 136 **Eosinophilic-specific protein contents correlate with the biophysical properties of mucus**

137 To determine whether the biophysical properties of the mucus were associated with the  
138 eosinophils in it, we measured the concentrations of the eosinophil-specific proteins galectin-10  
139 and eosinophil-derived neurotoxin (EDN). The concentrations of galectin-10 (**Figure 3A**) and  
140 EDN (**Figure 3B**) were significantly higher in mucus from patients with ECRS than in that from  
141 patients with non-ECRS (galectin-10,  $0.26 \pm 0.06$  vs  $0.008 \pm 0.005$ ,  $p < 0.01$ ; EDN,  $2.09 \pm 0.16$  vs  
142  $1.25 \pm 0.12$   $\mu\text{g/ml}$ ,  $p < 0.001$ ). In contrast, the concentration of neutrophil granule protein  
143 myeloperoxidase (MPO) was significantly higher in mucus from patients with non-ECRS ( $0.11 \pm$   
144  $0.11$  vs  $0.33 \pm 0.37$   $\mu\text{g/ml}$ ,  $p < 0.05$ , **Figure 3C**).

145 The correlations between these protein levels and the physical properties or CT values of  
146 mucus were analyzed (**Table 1**). Shear viscosity was positively correlated with levels of  
147 galectin-10 and EDN, dry weight was positively correlated with levels of galectin-10, contact  
148 angle was positively correlated with levels of galectin-10 and EDN but negatively correlated with  
149 MPO, and CT values were positively correlated with levels of galectin-10 and EDN. Taken  
150 together, these results support the hypothesis that the increased eosinophils in mucus contribute to  
151 its biophysical characteristics.

152

### 153 **Aggregated ETosis cells mimic mucus properties**

154 Unlike apoptosis, which is characterized by DNA fragmentation, activated eosinophils and  
155 neutrophils undergo ETosis to release filamentous ETs (23, 24). To investigate the hypothesis that  
156 ETotic granulocytes in the mucus are involved in its biophysical properties, isolated human  
157 eosinophils and neutrophils were stimulated with phorbol 12-myristate 13-acetate (PMA) to  
158 induce ETosis and were aggregated by shear-flow (**Figure 4A**) (25). The macroscopic appearance  
159 of cell aggregates showed significant differences; eosinophil aggregates (aggEETs) showed a  
160 yellow-brownish eraser-dust-like appearance, whereas neutrophil aggregates (aggNETs) showed a  
161 white gel-like appearance (**Figure 4B**). These aggregates consisted of accumulated ETs and cell  
162 debris (**Fig. S2**). The sections closely resembled clinical mucus (**Fig. 4C**).

163 The CT values of aggEETs were significantly higher than those of aggNETs (**Figure 4D**).  
164 Of note, the viscosity of aggEETs was higher than that of aggNETs and comparable to that of  
165 clinically obtained mucus from patients with ECRS (**Figure 4E**). In line with the mucus, the  
166 rheological properties of aggregated cells indicated a non-Newtonian shear-thinning pattern. The  
167 higher adhesion and viscosity of aggEETs were also confirmed using wall slip time-lapse images  
168 (**Movie S2**).

169 The weight reduction rate of aggNETs measured using the TGA was larger than that of  
170 aggEETs, and reached a plateau more quickly (**Figure 4F**). The final dry weight percentages of  
171 aggEETs and aggNETs were  $19.5\% \pm 5.7\%$  and  $8.0\% \pm 2.8\%$  ( $p < 0.01$ ) respectively (**Fig. 4G**). The  
172 interactions between water and polymer molecules of aggEETs and aggNETs assessed by  
173 differential scanning calorimetry (26) showed similar patterns (**Fig. S3**), indicating no difference  
174 in phase transition behavior and molecular mobility. The wettability assessed by the static water  
175 contact angle revealed that aggEETs showed significantly higher hydrophobicity than aggNETs  
176 ( $82.4^\circ \pm 2.1^\circ$  vs  $54.1^\circ \pm 2.8^\circ$ ,  $p < 0.0001$ , **Fig. 4H**). These results indicate that in terms of CT value,



177 viscosity, dry weight, and wettability, the aggEETs and aggNETs represented similar physical  
178 properties to eosinophil- and neutrophil-dominant mucus, respectively.

179

## 180 **Heparin enhances DNase-mediated EET degradation**

181 EETs are composed of approximately 30-nm-diameter condensed chromatin structures and  
182 are resistant to degradation by deoxyribonuclease 1 (DNase 1), having a longer half-life than NETs  
183 (25, 27). As heparin has been reported to relax NETs (28, 29), we treated EETs with heparin and  
184 studied their ultrastructure. Interestingly, scanning electron microscopy revealed that heparin had  
185 a thinning effect on EETs (**Fig. 5A**). Transmission electron microscopy also revealed that the  
186 aggregated nucleosome structure of EETs was decreased after heparin treatment (**Fig. 5B**).

187 Heparin-treated EETs consisted of smooth fibers and a globular domain, similar to the previously  
188 reported ultrastructure of NETs (3). The mean diameter of non-treated EETs was  $29.8 \pm 0.05 \mu\text{m}$ ,  
189 whereas that of heparin treated EETs was  $19.2 \pm 0.03 \mu\text{m}$  (**Fig. 5C**). The relaxation effect of  
190 heparin on EETs was observed within 5 minutes and was concentration dependent (**Fig. S4A**).

191 These results indicate the disorganization of the chromatin structure, presumably through a  
192 heparin and histone interaction (30). Indeed, the liquid phase interaction of histone and heparin  
193 was confirmed by the co-precipitation (**Fig. S4B, C**). Specifically, heparin-induced relaxation of  
194 EETs was canceled in the presence of excess histone (**Fig. S4D**).

195 To test whether heparin enhanced the DNase-mediated EET degradation, EETs were  
196 treated with DNase with or without heparin, and the amount of free DNA in the supernatant was  
197 quantified. Heparin itself did not increase the EET degradation, whereas DNase-induced EET  
198 degradation was significantly increased in the presence of heparin (**Fig. 5D**). These data lead us to

199 propose that the heparin-histone interaction relaxed the chromatin structure to promote  
200 DNase-mediated DNA degradation.

201

## 202 **Effect of heparin and DNase on aggEETs and mucus**

203 As aggregated cells were a complex of accumulated EETs and cell debris, we next aimed to  
204 study the effect of heparin and DNase 1 on the biophysical properties of aggEETs and aggNETs.  
205 In the static condition, we noticed that aggEETs were significantly more resistant to DNase than  
206 aggNETs, keeping their structure and DNA contents for 18 hours (**Fig. S5A**). Heparin induced a  
207 “swelling” effect on the aggEET structure and enhanced the DNase-mediated DNA degradation  
208 (**Fig. 6A, Fig. S5B**).

209 The change in shear viscosity was studied by short (1 hour) exposure of aggEETs to DNase  
210 and heparin (**Fig. 6B**). Compared with the control, the most significant decrease in viscosity was  
211 observed in the aggEETs co-treated with DNase and heparin. Regarding wettability, we found that  
212 the contact angle of the aggEETs treated with DNase, but not those treated with heparin, was  
213 significantly less than that of the control. Among the groups, treatment with DNase and heparin  
214 induced the most significant decrease in hydrophobicity (**Fig. 6C**). These results indicate that  
215 aggregated DNA contributed to the hydrophobicity of aggEETs, leading to DNase-resistant  
216 viscosity.

217 To extend our findings to clinical samples, we examined the effect of DNase and heparin  
218 on the viscosity and wettability of mucus from patients with ECRS. As expected, eosinophilic  
219 mucin treated with DNase and heparin showed reduced shear viscosity (**Fig. 7A**). Treatment with  
220 DNase or heparin alone did not affect the wettability of eosinophilic mucin, although co-treatment

221 with DNase and heparin significantly reduced the hydrophobicity (**Fig. 7B**). Collectively, these  
222 data indicate the therapeutic potential of heparin for facilitating DNase-induced enzymatic  
223 degradation of EETs.

224

## 225 **DISCUSSION**

226 The current study identified that intraluminal accumulation and activation of granulocytes  
227 contributes to the clinical properties of hyperconcentrated airway mucus and may serve as a  
228 therapeutic target. Airway mucus is a complex mixture of the following components: 1) mucus  
229 glycoprotein (mucin) derived from airway epithelial goblet cells and submucosal glands; 2)  
230 detached or migrated cell components and substances released from them; 3) serum-derived  
231 proteins such as leached albumin; 4) pathogens such as bacteria and viruses; 5) dust; 6)  
232 electrolytes; 7) substances associated with infection such as secretory IgA and other  
233 immunoglobulins, lactoferrin, lysozymes, and defensins (31). Of these components, studies on the  
234 viscosity of mucus have largely focused on the hypersecretion of mucin and biological changes to  
235 it, whereas recent evidence has revealed that granulocyte-derived ET polymers contribute to the  
236 physical characteristics of inflammatory mucus (32, 33).

237 Granulocytes are the front-line cells of innate immunity, have a short lifespan, and do not  
238 divide once they mature. They are produced in large numbers in the bone marrow and can rapidly  
239 accumulate at inflammatory sites from the blood circulation. Once entering the airways, activated  
240 granulocytes can capture pathogens by causing ETosis, and then kill them with cytotoxic  
241 protein-containing ETs (34). Unlike neutrophilic inflammation, the majority of eosinophilic  
242 airway diseases are caused by sterile allergic reactions and have pathological implications.  
243 Utilizing the granulocyte-rich mucus from patients with chronic rhinosinusitis and blood-derived

244 cells, our data indicated that the presence of aggregated ETotic eosinophils influences the  
245 biophysical characteristics of mucus. The CT values of sinus mucus were directly related to the  
246 presence of eosinophilic inflammation and its biophysical properties, supporting the utility of CT  
247 values for diagnosis and pathological evaluation in clinical practice.

248 Fixed airway obstruction due to eosinophilic mucus is a hallmark phenomenon of diverse  
249 eosinophilic upper and lower airway diseases. The water contact angle experiments indicated the  
250 hydrophobic properties of eosinophil-dominant mucus. Biochemically, water is the most abundant  
251 constituent in airway mucus, composing about 98% of it under normal conditions. When the water  
252 content is below 90%–93%, mucus inhibits the motility of cilia, producing mucus stasis (35). In  
253 the current study, the mucus from patients with ECRS and non-ECRS was highly dehydrated  
254 (59.4% and 80.6% water, respectively), far exceeding that required to inhibit mucociliary  
255 clearance. Poor mucus clearance directly causes reduced quality of life for patients. For instance,  
256 the presence of eosinophilic mucin is reported to be associated with recurrence after endoscopic  
257 sinus surgery for chronic rhinosinusitis (7). Granule proteins, cytokines, histones, and other  
258 alarmins released from inflammatory cells may cause epithelial damage and tissue remodeling  
259 when they remain intraluminally localized, generating muco-inflammatory positive feedback  
260 (35-37).

261 To study the effects of eosinophils and neutrophils on the biophysical properties of mucus,  
262 we utilized blood-derived granulocytes. Using ETotic cell aggregates, we were able to reproduce  
263 similar physical properties as those clinically observed in eosinophil- and neutrophil-dominant  
264 mucus. While the mechanisms of inflammation have been investigated using molecular and  
265 genetic approaches, we believe that our cell population-based approach provides a better  
266 understanding of the biophysical phenomena. Although the current study focused on the properties

267 of the mucus, a significant difference between hydrophilic aggNETs and hydrophobic aggEETs  
268 might account for formation of pathological features of diseased tissue such as neutrophilic  
269 abscess (38) and eosinophilic granuloma (39). Our results provide a strong argument for targeting  
270 excess granulocyte accumulation and ET formation as causes of tissue dysfunction.

271         Aerosolized recombinant human DNase 1 (dornase alpha) is an established treatment for  
272 patients with cystic fibrosis, where it promotes the hydrolysis of NETs in airway secretions (40,  
273 41). EETs have a well-conserved chromatin structure and are more aggregated than NETs,  
274 resulting in greater stability against DNase (25, 42). The current study is the first demonstration of  
275 the relaxing effect of heparin on EETs. Negatively charged heparin has a high affinity for  
276 positively charged histones, and it can disorganize chromatin fiber by liberating histones (29, 43).  
277 Heparin has pleiotropic effects, such as preventing the cytotoxic effects of extracellular histone  
278 (44) and eosinophil granule proteins (45, 46). Our data support the combined use of heparin and  
279 DNase by inhalation, endoscopic injection, or irrigation, with the potential to remove EETs to  
280 decrease the viscosity and hydrophobicity of eosinophil-dominant mucus (**Fig. 7C**). This simple  
281 mucus modification strategy could be a better approach than targeting the mucin hypersecretion  
282 pathway, which is subject to adverse consequences (47).

283         Limitations of the current case-control study include the heterogeneity of chronic  
284 rhinosinusitis. In both ECRS and non-ECRS, chronic rhinosinusitis is classified according to the  
285 JESREC scoring system, although the pathogenesis is a mixture of inflammation by neutrophils  
286 and eosinophils in varying degrees (48). Nevertheless, the concentrations of eosinophil-specific  
287 galectin-10 and EDN in mucus were associated with their properties, suggesting the importance of  
288 eosinophil density. Considering the limitations of our experimental study, we could not exclude  
289 the possibility of the presence of EET-independent granulocyte viscosity. AggEETs and aggNETs

290 are composed of condensed cell debris including actin polymer, which may cause viscosity (22).  
291 Since neutrophils contain abundant protease that may degrade organized proteins (25), it is  
292 conceivable that neutrophil cell debris has a much more disintegrated structure. Other possibilities  
293 include cytolytic eosinophil production of *de novo* polymers such as Charcot-Leyden crystals (49),  
294 and amyloid-like aggregation of granule protein (4, 45, 50). The difference between neutrophil and  
295 eosinophil debris may be related to pathological differences, and further investigation is  
296 warranted.

297 In conclusion, our study revealed the characteristics of mucus and aggregated cells using  
298 radiographical, biophysical, pathological, and molecular approaches. The current study also  
299 highlights the utility of cell-population-based biophysical analysis. Intraluminal granulocyte  
300 accumulation and the activation of these granulocytes to form aggregated ETs are processes  
301 involved in the clinical features of mucus. The combination of DNase and heparin may be a  
302 promising therapeutic modality against highly viscous eosinophilic mucus.

303

## 304 **MATERIALS AND METHODS**

### 305 **Study design**

306 This was a case-control study comparing the CT values and physical properties of  
307 clinically obtained sinus mucus from age- and gender-matched ECRS and non-ECRS patients  
308 (**Table S1**). The sample size was based on preliminary data from our laboratory. Sinus mucus was  
309 obtained from patients with non-ECRS and those with ECRS treated by routine endoscopic sinus  
310 surgery between February 2017 and July 2019. Samples were immediately frozen at  $-30^{\circ}\text{C}$  and  
311 shipped to Akita University on dry ice and stored at  $-80^{\circ}\text{C}$ . Patients with ECRS were diagnosed

312 according to the diagnostic criteria of the JESREC study score (51). This scoring system assesses  
313 unilateral or bilateral disease, the presence of nasal polyps, blood eosinophilia, and dominant  
314 shadow of ethmoid sinuses on CT scans. For a definitive diagnosis of ECRS, a score of 11 or  
315 higher and a mean number of 70 or higher infiltrated eosinophil counts in sectioned tissue in the  
316 three densest areas of cell infiltration in high power fields ( $\times 400$ , hematoxylin-eosin staining) is  
317 required. Patients who did not meet the diagnosis of ECRS were classified as non-ECRS. Patients  
318 with an established immunodeficiency, coagulation disorder, diagnosis of classic allergic fungal  
319 sinusitis, eosinophilic granulomatosis with polyangiitis, fungal sinusitis, or cystic fibrosis, and  
320 those who were pregnant, were excluded from the study. All patients scheduled for surgery had  
321 previously failed to respond to adequate trials of conservative medical therapy administered to  
322 control their symptoms. All patients were free of systemic steroids for at least two months prior to  
323 surgery. Preoperative demographics and medical history including sex and age were obtained for  
324 each patient. For the mucus studies, the experiments were conducted with the investigator blinded  
325 to the details of the samples.

326         The purpose of the experimental study using mucus from patients with ECRS and cell  
327 aggregates separately dominated by neutrophils or eosinophils was to investigate the mechanism  
328 behind the highly viscous eosinophilic airway mucus with a view to developing a rationally  
329 designed treatment. For the cell-based studies, measurements were made over at least three  
330 experiments. All experiments were approved by the Akita University institutional review board,  
331 protocol approval No. 994, 1965. Written informed consent was obtained from all participants in  
332 accordance with the principles laid out in the Declaration of Helsinki.

333

### 334 **Cell purification**

335 Eosinophils were isolated from peripheral blood from medication-free donors using a  
336 MACS™ system (Miltenyi Biotec, Bergisch Gladbach, Germany) with CD16-negative selection  
337 (anti-CD16 antibody-conjugated microbeads, #130-045-701, Miltenyi Biotec), as described  
338 previously (52, 53). The purity of the isolated eosinophils was >98% of nucleated cells and the  
339 viability >99%. Neutrophils (>95% neutrophils, viability >98%) were obtained by positive  
340 selection using the same system. The viability and purity of the cells were analyzed via trypan blue  
341 exclusion.

342

### 343 **Ex vivo CT value measurement**

344 Nasal mucus and cell aggregates were stored in microtubes and scanned three times using  
345 an Aquilion ONE CT scanner (**Fig. S1**, Canon Medical Systems, Otawara, Japan). The scanning  
346 parameters were 120 kVp, 240 mA, 0.5-s exposure time, and 350-mm field of view. The raw data  
347 were reconstructed with an FC 21 kernel to generate 512×512 matrix images with 0.5-mm slice  
348 thickness ( $0.67 \times 0.67 \times 0.5$ -mm voxel resolution). Each voxel had a CT value that represented the  
349 x-ray attenuation of a substance where 0 Hounsfield units (HU) is the attenuation of water  
350 ( $1\text{g/cm}^3$ ) and  $-1000$  HU is the attenuation of air ( $0\text{g/cm}^3$ ). The microtubes were excluded from the  
351 obtained CT images by applying a cut-off CT threshold of  $-100$  HU and the mucus was extracted.  
352 The CT values of the mucus were measured on each of the three scans and then averaged.

353

### 354 **Preparation and characterization of ETosis cell aggregates**

355 Isolated neutrophils and eosinophils ( $10\text{--}100 \times 10^6$  cells) were stimulated with phorbol  
356 12-myristate 13-acetate (PMA; Sigma, 10 ng/ml) in 6-well flat-bottom tissue culture plates, in



357 0.3% bovine serum albumin (BSA) containing phenol red-free RPMI 1640. After 18 hours (>99%  
358 cell death with ETosis), culture plates were shaken ( $600 \text{ minutes}^{-1}$ , 20 minutes) with an MS1 plate  
359 shaker (IKA Works, Wilmington, NC) to induce aggregates. The aggregates were collected using  
360 a cell scraper and tweezers. In some experiments, they were fixed in 10% formalin and embedded  
361 in paraffin, followed by hematoxylin-eosin staining. For liquid phase stability, aggregates were  
362 stained with SYTOX green (1:5000) and viewed by an inverted microscope (Eclipse TE300,  
363 Nikon, Tokyo, Japan) equipped with a cooled color digital camera (Spot 1.3.0, Diagnostic  
364 Instruments, Sterling Heights, MI) in conjunction with IP Lab image analysis software  
365 (Scanalytics, Fairfax, VA). Additional characterization is provided in **Fig. S2**.

366

### 367 **Measurement of shear viscosity**

368 The rheological experiments were carried out using an MCR302 rotational rheometer  
369 (Anton Paar Japan, Tokyo, Japan) with a cone–plate system (CP25-2) for shear fixation.  
370 Frequency sweep tests were performed from  $0.1 \text{ rad/s}$  to  $100 \text{ rad/s}$ . The shear thinning behavior  
371 of secretions and cell aggregates was characterized over a range of 0 to  $100 \text{ s}^{-1}$ . The viscosity of  
372 the sample against shear rate was measured. All rheology studies were performed at  $36^\circ\text{C}$ . In some  
373 experiments, the shear viscosity was also measured with added DNase 1 (40 U/ml, New England  
374 Biolabs, Ipswich, MA) and/or heparin (300  $\mu\text{g/ml}$ , Sigma-Aldrich, St. Louis, MO). DNase and/or  
375 heparin were added in sufficient quantities to soak the samples in the tubes and the tubes were  
376 incubated for one hour at  $37^\circ\text{C}$ . Before measurement of the shear viscosity, 20 mg of each sample  
377 was prepared.

378

379 **Thermogravimetric analysis (TGA)**

380 A sample of each of the cell aggregates or mucus (5 mg) was placed in an alumina crucible  
381 and heated in a thermogravimetric analyzer (STA 7300, Hitachi High-Technologies, Tokyo,  
382 Japan). Samples (originally at 25°C) were heated at a rate of 10°C/minute up to a maximum of  
383 100°C and were maintained at this temperature for 30 minutes in a stream of dry nitrogen. The  
384 percentage weight change was evaluated, and the final weight was considered as the dry weight.

385

386 **Water contact angle analysis**

387 Mucus or cell aggregates were uniformly smeared onto a slide and dried in ambient air for  
388 6 hours. For measurement of the contact angle, a 4- $\mu$ l water droplet was placed using a  
389 manipulator and imaged using a digital camera 30 s after the release of the droplet. The contact  
390 angle values of the droplets were recorded using the ImageJ contact angle plug-in  
391 (<https://imagej.nih.gov/ij/>). In some experiments, we also measured the contact angle of samples  
392 treated overnight with DNase 1 (40 U/ml) and/or heparin (300  $\mu$ g/ml, Sigma-Aldrich, St. Louis,  
393 MO). Prepared samples were smeared onto a slide and the contact angle was measured as  
394 described above.

395

396 **Measurement of the levels of EDN, galectin-10, and MPO**

397 Ten microliters of 0.1% dithiothreitol were added to 10-mg mucus samples, which were  
398 then stirred for 15 minutes before being quickly frozen in liquid nitrogen. The samples were  
399 crushed with a multi-bead shocker (Yasui Kikai, Osaka, Japan) at 250 bpm for 10 s and then with  
400 an ultrasonic crusher (Bioruptor, BM Equipment Co., Ltd. Tokyo, Japan). The supernatant was

401 collected by centrifugation (10 000× g, 10 minutes). The levels of EDN, galectin-10, and MPO  
402 were measured using ELISA assay kits (EDN: 7630, MBL, Nagoya, Japan; galectin-10:  
403 Cloud-Clone Corp., Katy, TX, MBL, Aichi, Japan; MPO: Enzo Life Sciences Inc, Farmingdale,  
404 NY).

405

#### 406 **Scanning electron microscopy (SEM)**

407 Eosinophils were added to round coverslips in culture plates and stimulated with PMA (10  
408 ng/ml) for 3 hours or more to induce EET formation, with or without heparin (300 µg/ml, 30  
409 minutes). They were then immediately fixed in a mixture of freshly prepared aldehydes (1%  
410 glutaraldehyde and 1% paraformaldehyde) in 0.1 M phosphate buffer (pH 7.4) for 1 hour at room  
411 temperature and processed for SEM. Coverslip-adherent cells were postfixed with 1% osmium  
412 tetroxide in water for 1 hour and dehydrated in an ascending ethanol series from 50% (vol/vol) to  
413 absolute ethanol (10 minutes per step). Cells were then critical point dried in carbon dioxide.  
414 Coverslips were mounted on aluminum holders, sputtered with 5-nm gold, and analyzed in a  
415 scanning electron microscope (Thermo Fisher Scientific FEI Quanta 3D FEG Dual Beam  
416 (SEM/FIB)], which enabled excellent high resolution surface imaging.

417 Qualitative analyses were performed on 70 electron micrographs (n=35 for each group) at  
418 different magnifications. For quantitative analyses of EETs, a total of 20 electron micrographs  
419 from cytolytic eosinophils showing EETs (10 from untreated and 10 from heparin-treated cells)  
420 were analyzed at 80 000×. The diameters of 20 EET fibers randomly selected from each electron  
421 micrograph were measured, with a total of 400 fibers being analyzed (n=200 fibers in each group).  
422 The mean diameter of the EET fibers was then determined for each group.

423

## 424 **Transmission electron microscopy (TEM)**

425 Eosinophils were seeded on Aclar film (Nishin EM, Tokyo, Japan), stimulated with 10  
426 ng/ml of PMA for 3 hours, and then immediately fixed in a mixture of freshly prepared aldehydes  
427 (1.25% glutaraldehyde and 1% paraformaldehyde) in 0.1 M cacodylate buffer. After incubation  
428 for 2 hours in 0.1 M cacodylate buffer containing 1% OsO<sub>4</sub>, the specimens were dehydrated in an  
429 ethanol series, passed through propylene oxide, and embedded in epoxy resin. Ultrathin sections  
430 (80 nm) were collected on copper grids and stained for 20 minutes in 4% uranyl acetate and 0.5%  
431 lead citrate. The specimens were viewed with a Hitachi H-7650 transmission electron microscope  
432 at 100 kV.

433

## 434 **EET and aggEET dissolution assays**

435 Isolated eosinophils were induced to ETosis by stimulation with PMA (10 ng/ml) for 18  
436 hours. The medium was replaced with 100 µl of Ca<sup>2+</sup>-containing Hank's balanced salt solution  
437 with Picogreen (Thermo Fisher Scientific, Waltham, MA, 1:100) and incubated with or without  
438 DNase 1 (20 U/ml) and heparin (5 mg/ml). The plate was shaken gently (400 rpm) for 5 minutes at  
439 room temperature. After pipetting, 100 µl of medium was aspirated and centrifuged (500× g, 5  
440 minutes). The fluorescence intensity of the supernatant was immediately measured to quantify the  
441 free DNA using a GloMax-Multi detection system (Promega, Madison, WI). In the static  
442 condition, aggEETs were incubated at 37°C (0.3% BSA/RPMI medium) in the presence of DNase  
443 1 (40 U/ml). To visualize DNA, SYTOX was added to the medium. Fluorescent images were

444 obtained at indicated time points under an inverted microscope (Eclipse TE300, Nikon, Tokyo,  
445 Japan) equipped with a cooled color digital camera.

446

#### 447 **Statistical Analysis**

448 Results are expressed as mean  $\pm$  SD. The data analysis in this study was performed using  
449 GraphPad Prism software, Version 7 (GraphPad, San Diego, USA). The Wilcoxon signed rank test  
450 or Welch's *t* test were used to evaluate differences between two groups. Multiple comparison tests  
451 were used to compare means between groups. Correlation analysis was performed using  
452 Spearman's rank correlation. A *p*-value of  $<0.05$  was considered statistically significant.

453

#### 454 **List of Supplementary Materials**

455 **Fig. S1.** Computed tomography (CT) imaging of mucus and cell aggregate samples

456 **Fig. S2.** Structures of aggregated eosinophil extracellular traps (aggEETs) and aggregated  
457 neutrophil extracellular traps (aggNETs)

458 **Fig. S3.** Differential scanning calorimetry (DSC) chart of aggEETs and aggNETs

459 **Fig. S4.** Heparin-induced relaxation ability on EETs

460 **Fig. S5.** Stability of aggEETs and aggNETs against DNase

461 **Table S1.** Clinical characteristics of patients with eosinophilic chronic rhinosinusitis (ECRS) and  
462 non-eosinophilic chronic rhinosinusitis (non-ECRS).

463 **Movie S1.** Surgical removal of sinus mucus

464 **Movie S2.** Wall slip time-lapse images

465

466 References and Notes

- 467 1. J. Widdicombe, Relationships among the composition of mucus, epithelial lining liquid,  
468 and adhesion of microorganisms. *Am. J. Respir. Crit. Care Med.* **151**, 2088-2092;  
469 discussion 2092-2083 (1995).
- 470 2. J. C. Hogg, F. S. F. Chu, W. C. Tan, D. D. Sin, S. A. Patel, P. D. Pare, F. J. Martinez, R. M.  
471 Rogers, B. J. Make, G. J. Criner, R. M. Cherniack, A. Sharafkhaneh, J. D. Luketich, H. O.  
472 Coxson, W. M. Elliott, F. C. Sciurba, Survival after Lung Volume Reduction in Chronic  
473 Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* **176**, 454-459 (2007).
- 474 3. V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y.  
475 Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria. *Science* **303**,  
476 1532-1535 (2004).
- 477 4. S. Ueki, R. C. N. Melo, I. Ghiran, L. A. Spencer, A. M. Dvorak, P. F. Weller, Eosinophil  
478 extracellular DNA trap cell death mediates lytic release of free secretion-competent  
479 eosinophil granules in humans. *Blood* **121**, 2074-2083 (2013).
- 480 5. N. Ohta, S. Ueki, Y. Konno, M. Hirokawa, T. Kubota, S. Tomioka-Matsutani, T. Suzuki,  
481 Y. Ishida, T. Kawano, T. Miyasaka, T. Takahashi, T. Suzuki, I. Ohno, S. Kakehata, S.  
482 Fujieda, ETosis-derived DNA trap production in middle ear effusion is a common feature  
483 of eosinophilic otitis media. *Allergol Int* **67**, 414-416 (2018).
- 484 6. R. G. Slavin, Sinusitis: viral, bacterial, or fungal and what is the role of Staph? *Allergy*  
485 *Asthma Proc.* **27**, 447-450 (2006).
- 486 7. S. Vlaminck, T. Vauterin, P. W. Hellings, M. Jorissen, F. Acke, P. Van Cauwenberge, C.  
487 Bachert, P. Gevaert, The importance of local eosinophilia in the surgical outcome of  
488 chronic rhinosinusitis: a 3-year prospective observational study. *Am J Rhinol Allergy* **28**,  
489 260-264 (2014).
- 490 8. J. P. Bent, 3rd, F. A. Kuhn, Diagnosis of allergic fungal sinusitis. *Otolaryngol. Head Neck*  
491 *Surg.* **111**, 580-588 (1994).
- 492 9. S. Ueki, A. Hebisawa, M. Kitani, K. Asano, J. S. Neves, Allergic Bronchopulmonary  
493 Aspergillosis—A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death.  
494 *Front. Immunol.* **9**, 2346 (2018).
- 495 10. R. Goyal, C. S. White, P. A. Templeton, E. J. Britt, L. J. Rubin, High attenuation mucous  
496 plugs in allergic bronchopulmonary aspergillosis: CT appearance. *J. Comput. Assist.*  
497 *Tomogr.* **16**, 649-650 (1992).
- 498 11. P. M. Logan, N. L. Müller, High-attenuation mucous plugging in allergic  
499 bronchopulmonary aspergillosis. *Can. Assoc. Radiol. J.* **47**, 374-377 (1996).
- 500 12. K. Ikari, J. Tezuka, T. Matsumoto, M. Tsuji, M. Kawamura, T. Oda, S. Ueki,  
501 Charcot–Leyden Crystals in Rapidly Progressing Plastic Bronchitis. *Am. J. Respir. Crit.*  
502 *Care Med.* **204**, e54-e55 (2021).
- 503 13. M. Yoshida, Y. Miyahara, K. Orimo, N. Kono, M. Narita, Y. Ohya, K. Matsumoto, S.  
504 Nakagawa, S. Ueki, H. Morita, I. Miyairi, Eosinophil Extracellular Traps in the Casts of  
505 Plastic Bronchitis Associated With Influenza Virus Infection. *Chest* **160**, 854-857 (2021).
- 506 14. L. M. Kuyper, P. D. Pare, J. C. Hogg, R. K. Lambert, D. Ionescu, R. Woods, T. R. Bai,  
507 Characterization of airway plugging in fatal asthma. *Am. J. Med.* **115**, 6-11 (2003).

- 508 15. W. V. Filley, K. E. Holley, G. M. Kephart, G. J. Gleich, Identification by  
509 immunofluorescence of eosinophil granule major basic protein in lung tissues of patients  
510 with bronchial asthma. *Lancet* **2**, 11-16 (1982).
- 511 16. S. Svenningsen, E. Haider, C. Boylan, M. Mukherjee, R. L. Eddy, D. P. I. Capaldi, G.  
512 Parraga, P. Nair, CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma.  
513 *Chest* **155**, 1178-1189 (2019).
- 514 17. S. Ueki, T. Tokunaga, S. Fujieda, K. Honda, M. Hirokawa, L. A. Spencer, P. F. Weller,  
515 Eosinophil ETosis and DNA Traps: a New Look at Eosinophilic Inflammation. *Curr.*  
516 *Allergy Asthma Rep.* **16**, 54 (2016).
- 517 18. W. J. Fokkens, V. J. Lund, C. Hopkins, P. W. Hellings, R. Kern, S. Reitsma, S.  
518 Toppila-Salmi, M. Bernal-Sprekelsen, J. Mullol, I. Alobid, W. Terezinha Anselmo-Lima,  
519 C. Bachert, F. Baroody, C. Von Buchwald, A. Cervin, N. Cohen, J. Constantinidis, L. De  
520 Gabory, M. Desrosiers, Z. Diamant, R. G. Douglas, P. H. Gevaert, A. Hafner, R. J. Harvey,  
521 G. F. Joos, L. Kalogjera, A. Knill, J. H. Kocks, B. N. Landis, J. Limpens, S. Lebeer, O.  
522 Lourenco, P. M. Matricardi, C. Meco, L. O'Mahony, C. M. Philpott, D. Ryan, R.  
523 Schlosser, B. Senior, T. L. Smith, T. Teeling, P. V. Tomazic, D. Y. Wang, D. Wang, L.  
524 Zhang, A. M. Agius, C. Ahlstrom-Emanuelsson, R. Alabri, S. Albu, S. Alhabash, A.  
525 Aleksic, M. Aloulah, M. Al-Qudah, S. Alsaleh, M. A. Baban, T. Baudoin, T. Balvers, P.  
526 Battaglia, J. D. Bedoya, A. Beule, K. M. Bofares, I. Braverman, E. Brozek-Madry, B.  
527 Richard, C. Callejas, S. Carrie, L. Caulley, D. Chussi, E. de Corso, A. Coste, L. Devyani,  
528 U. El Hadi, A. Elfarouk, P. H. Eloy, S. Farrokhi, G. Felisati, M. D. Ferrari, R. Fishchuk, J.  
529 W. Grayson, P. M. Goncalves, B. Grdinic, V. Grgic, A. W. Hamizan, J. V. Heinichen, S.  
530 Husain, T. I. Ping, J. Ivaska, F. Jakimovska, L. Jovancevic, E. Kakande, R. Kamel, S.  
531 Karpischenko, H. H. Kariyawasam, A. Kjeldsen, L. Klimek, S. W. Kim, J. J. Letort, A.  
532 Lopatin, A. Mahdjoubi, J. Netkovski, D. N. Tshipukane, A. Obando-Valverde, M. Okano,  
533 M. Onerci, Y. K. Ong, R. Orlandi, K. Ouenoughy, M. Ozkan, A. Peric, J. Plzak, E.  
534 Prokopakis, N. Prepageran, A. Psaltis, B. Pugin, M. Raftopoulos, P. Rombaux, S. Sahtout,  
535 C. C. Sarafoleanu, K. Searyoh, C. S. Rhee, J. Shi, M. Shkoukani, A. K. Shukuryan, M.  
536 Sicak, D. Smyth, K. Snidvongs, T. S. Kosak, P. Stjarne, B. Sutikno, S. Steinsvag, P.  
537 Tantilipikorn, S. Thanaviratananich, T. Tran, J. Urbancic, A. Valiulis, C. V. De Aparicio,  
538 D. Vicheva, P. M. Virkkula, G. Vicente, R. Voegels, M. M. Wagenmann, R. S. Wardani,  
539 A. Welge-Lussen, I. Witterick, E. Wright, D. Zabolotniy, B. Zsolt, C. P. Zwetsloot,  
540 European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology journal* **0**,  
541 1-464 (2020).
- 542 19. J. W. Grayson, M. Cavada, R. J. Harvey, Clinically relevant phenotypes in chronic  
543 rhinosinusitis. *J. Otolaryngol. - Head Neck Surg.* **48**, 23 (2019).
- 544 20. T. S. Panchabhai, S. Mukhopadhyay, S. Sehgal, D. Bandyopadhyay, S. C. Erzurum, A. C.  
545 Mehta, Plugs of the Air Passages: A Clinicopathologic Review. *Chest* **150**, 1141-1157  
546 (2016).
- 547 21. W. P. Dillon, P. M. Som, G. D. Fullerton, Hypointense MR signal in chronically  
548 inspissated sinonasal secretions. *Radiology* **174**, 73-78 (1990).
- 549 22. S. K. Lai, Y. Y. Wang, D. Wirtz, J. Hanes, Micro- and macrorheology of mucus. *Adv Drug*  
550 *Deliv Rev* **61**, 86-100 (2009).
- 551 23. V. H. Neves, C. Palazzi, K. Bonjour, S. Ueki, P. F. Weller, R. C. N. Melo, In Vivo ETosis  
552 of Human Eosinophils: The Ultrastructural Signature Captured by TEM in Eosinophilic  
553 Diseases. *Front. Immunol.* **13**, 938691 (2022).

- 554 24. M. Fukuchi, Y. Miyabe, C. Furutani, T. Saga, Y. Moritoki, T. Yamada, P. F. Weller, S.  
555 Ueki, How to detect eosinophil ETosis (EETosis) and extracellular traps. *Allergology*  
556 *International* **70**, 19-29 (2021).
- 557 25. S. Ueki, Y. Konno, M. Takeda, Y. Moritoki, M. Hirokawa, Y. Matsuwaki, K. Honda, N.  
558 Ohta, S. Yamamoto, Y. Takagi, A. Wada, P. F. Weller, Eosinophil extracellular trap cell  
559 death-derived DNA traps: Their presence in secretions and functional attributes. *J. Allergy*  
560 *Clin. Immunol.* **137**, 258-267 (2016).
- 561 26. M. Tanaka, T. Hayashi, S. Morita, The roles of water molecules at the biointerface of  
562 medical polymers. *Polymer Journal* **45**, 701-710 (2013).
- 563 27. T. Hashimoto, S. Ueki, Y. Kamide, Y. Miyabe, M. Fukuchi, Y. Yokoyama, T. Furukawa,  
564 N. Azuma, N. Oka, H. Takeuchi, K. Kanno, A. Ishida-Yamamoto, M. Taniguchi, A.  
565 Hashiramoto, K. Matsui, Increased Circulating Cell-Free DNA in Eosinophilic  
566 Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and  
567 Immunothrombosis. *Front. Immunol.* **12**, 801897 (2021).
- 568 28. T. A. Fuchs, A. Brill, D. Duerschmied, D. Schatzberg, M. Monestier, D. D. Myers, Jr., S.  
569 K. Wroblewski, T. W. Wakefield, J. H. Hartwig, D. D. Wagner, Extracellular DNA traps  
570 promote thrombosis. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 15880-15885 (2010).
- 571 29. R. Chen, R. Kang, X. G. Fan, D. Tang, Release and activity of histone in diseases. *Cell*  
572 *Death Dis.* **5**, e1370-e1370 (2014).
- 573 30. B. Villeponteau, Heparin increases chromatin accessibility by binding the trypsin-sensitive  
574 basic residues in histones. *Biochem. J.* **288** ( Pt 3), 953-958 (1992).
- 575 31. R. A. Cone, Barrier properties of mucus. *Adv Drug Deliv Rev* **61**, 75-85 (2009).
- 576 32. S. Ueki, N. Ohta, M. Takeda, Y. Konno, M. Hirokawa, Eosinophilic Otitis Media: the  
577 Aftermath of Eosinophil Extracellular Trap Cell Death. *Curr. Allergy Asthma Rep.* **17**, 33  
578 (2017).
- 579 33. G. Sollberger, D. O. Tilley, A. Zychlinsky, Neutrophil Extracellular Traps: The Biology of  
580 Chromatin Externalization. *Dev. Cell* **44**, 542-553 (2018).
- 581 34. H. Nagase, S. Ueki, S. Fujieda, The roles of IL-5 and anti-IL-5 treatment in eosinophilic  
582 diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic  
583 rhinosinusitis. *Allergol Int* **69**, 178-186 (2020).
- 584 35. R. C. Boucher, Muco-Obstructive Lung Diseases. *N. Engl. J. Med.* **380**, 1941-1953 (2019).
- 585 36. C. R. Esther, M. S. Muhlebach, C. Ehre, D. B. Hill, M. C. Wolfgang, M. Kesimer, K. A.  
586 Ramsey, M. R. Markovetz, I. C. Garbarine, M. G. Forest, I. Seim, B. Zorn, C. B. Morrison,  
587 M. F. Delion, W. R. Thelin, D. Villalon, J. R. Sabater, L. Turkovic, S. Ranganathan, S. M.  
588 Stick, R. C. Boucher, Mucus accumulation in the lungs precedes structural changes and  
589 infection in children with cystic fibrosis. *Sci. Transl. Med.* **11**, eaav3488 (2019). doi:  
590 10.1126/scitranslmed.aav3488.
- 591 37. S. Ueki, Y. Miyabe, Y. Yamamoto, M. Fukuchi, M. Hirokawa, L. A. Spencer, P. F. Weller,  
592 Charcot-Leyden Crystals in Eosinophilic Inflammation: Active Cytolysis Leads to Crystal  
593 Formation. *Curr. Allergy Asthma Rep.* **19**, 35 (2019). doi: 10.1007/s11882-019-0868-0.
- 594 38. V. Papayannopoulos, Neutrophil extracellular traps in immunity and disease. *Nat. Rev.*  
595 *Immunol.* **18**, 134-147 (2018).
- 596 39. K. K. Malta, C. Palazzi, V. H. Neves, Y. Aguiar, T. P. Silva, R. C. N. Melo,  
597 Schistosomiasis Mansonii-Recruited Eosinophils: An Overview in the Granuloma Context.  
598 *Microorganisms* **10**, (2022). doi: 10.3390/microorganisms10102022.



- 599 40. S. Shak, D. J. Capon, R. Hellmiss, S. A. Marsters, C. L. Baker, Recombinant human DNase  
600 I reduces the viscosity of cystic fibrosis sputum. *Proceedings of the National Academy of*  
601 *Sciences* **87**, 9188-9192 (1990).
- 602 41. H. J. Fuchs, D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey,  
603 B. J. Rosenstein, A. L. Smith, M. E. Wohl, Effect of Aerosolized Recombinant Human  
604 DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients  
605 with Cystic Fibrosis. *N. Engl. J. Med.* **331**, 637-642 (1994).
- 606 42. T. Hashimoto, S. Ueki, Y. Kamide, Y. Miyabe, M. Fukuchi, Y. Yokoyama, T. Furukawa,  
607 N. Azuma, N. Oka, H. Takeuchi, K. Kanno, A. Ishida-Yamamoto, M. Taniguchi, A.  
608 Hashiramoto, K. Matsui, Increased Circulating Cell-Free DNA in Eosinophilic  
609 Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and  
610 Immunothrombosis. *Front. Immunol.* **12**, 801897 (2021).
- 611 43. J. Homa, W. Ortmann, E. Kolaczowska, Conservative Mechanisms of Extracellular Trap  
612 Formation by Annelida *Eisenia andrei*: Serine Protease Activity Requirement. *PLoS One*  
613 **11**, e0159031 (2016).
- 614 44. K. C. A. A. Wildhagen, P. García De Frutos, C. P. Reutelingsperger, R. Schrijver, C.  
615 Aresté, A. Ortega-Gómez, N. M. Deckers, H. C. Hemker, O. Soehnlein, G. A. F. Nicolaes,  
616 Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves  
617 survival in sepsis. *Blood* **123**, 1098-1101 (2014).
- 618 45. K. R. Acharya, S. J. Ackerman, Eosinophil Granule Proteins: Form and Function. *J. Biol.*  
619 *Chem.* **289**, 17406-17415 (2014).
- 620 46. D. J. Adamko, Y. Wu, F. Ajamian, R. Ilarraza, R. Moqbel, G. J. Gleich, The effect of  
621 cationic charge on release of eosinophil mediators. *J. Allergy Clin. Immunol.* **122**, 383-390,  
622 390 e381-384 (2008).
- 623 47. S. Yuan, M. Hollinger, M. E. Lachowicz-Scroggins, S. C. Kerr, E. M. Dunican, B. M.  
624 Daniel, S. Ghosh, S. C. Erzurum, B. Willard, S. L. Hazen, X. Huang, S. D. Carrington, S.  
625 Oscarson, J. V. Fahy, Oxidation increases mucin polymer cross-links to stiffen airway  
626 mucus gels. *Sci. Transl. Med.* **7**, 276ra227 (2015).
- 627 48. T. Delemarre, B. S. Bochner, H.-U. Simon, C. Bachert, Rethinking neutrophils and  
628 eosinophils in chronic rhinosinusitis. *J. Allergy Clin. Immunol.* **148**, 327-335 (2021).
- 629 49. S. Ueki, T. Tokunaga, R. C. N. Melo, H. Saito, K. Honda, M. Fukuchi, Y. Konno, M.  
630 Takeda, Y. Yamamoto, M. Hirokawa, S. Fujieda, L. A. Spencer, P. F. Weller,  
631 Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap  
632 cell death. *Blood* **132**, 2183-2187 (2018).
- 633 50. J. S. Erjefalt, L. Greiff, M. Andersson, E. Matsson, H. Petersen, M. Linden, T. Ansari, P.  
634 K. Jeffery, C. G. Persson, Allergen-induced eosinophil cytolysis is a primary mechanism  
635 for granule protein release in human upper airways. *Am. J. Respir. Crit. Care Med.* **160**,  
636 304-312 (1999).
- 637 51. T. Tokunaga, M. Sakashita, T. Haruna, D. Asaka, S. Takeno, H. Ikeda, T. Nakayama, N.  
638 Seki, S. Ito, J. Murata, Y. Sakuma, N. Yoshida, T. Terada, I. Morikura, H. Sakaida, K.  
639 Kondo, K. Teraguchi, M. Okano, N. Otori, M. Yoshikawa, K. Hirakawa, S. Haruna, T.  
640 Himi, K. Ikeda, J. Ishitoya, Y. Iino, R. Kawata, H. Kawauchi, M. Kobayashi, T. Yamasoba,  
641 T. Miwa, M. Urashima, M. Tamari, E. Noguchi, T. Ninomiya, Y. Imoto, T. Morikawa, K.  
642 Tomita, T. Takabayashi, S. Fujieda, Novel scoring system and algorithm for classifying  
643 chronic rhinosinusitis: the JESREC Study. *Allergy* **70**, 995-1003 (2015).

- 644 52. S. Ueki, G. Mahemuti, H. Oyamada, H. Kato, J. Kihara, M. Tanabe, W. Ito, T. Chiba, M.  
645 Takeda, H. Kayaba, J. Chihara, Retinoic acids are potent inhibitors of spontaneous human  
646 eosinophil apoptosis. *J. Immunol.* **181**, 7689-7698 (2008).  
647 53. S. Ueki, J. Kihara, H. Kato, W. Ito, M. Takeda, Y. Kobayashi, H. Kayaba, J. Chihara,  
648 Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. *Allergy*  
649 **64**, 718-724 (2009).

650

651 **Acknowledgments:** The authors are grateful to Noriko Tan, Satomi Misawa, Nozomi Tanaka, and  
652 Chikako Furutani for their outstanding technical assistance. We thank Satoshi Marumo for  
653 helpful discussion and Edanz (<https://jp.edanz.com/ac>) for editing a draft of this  
654 manuscript.

655

656 **Funding:**

657 AstraZeneca Evidence Connect Externally Sponsored Research (SU)

658 Charitable Trust Laboratory Medicine Research Foundation of Japan (SU)

659 JSPS KAKENHI 15KK0329, 20K08794, 21K08434, and 21K07833 (SU)

660 JSPS KAKENHI 17K09993 (MT)

661 JSPS KAKENHI 17K17611 (YK).

662 JSPS KAKENHI 22K08598 (IM)

663 JSPS KAKENHI 17K11356, 25293348, and 20H03832 (TY)

664 Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical  
665 Research and Development JP22ek0410097 (KA)

666 Conselho Nacional de Desenvolvimento Científico e Tecnológico 406019 and 309734 (RCNM)

667 Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) (RCNM)

668

669 **Author contributions:**

670 Conceptualization: YM, SU

671 Methodology: SU, YM, MF, MJ, NT, RCNM

672 Investigation: YM, MF, HT, YN, MJ, YM, MA, YK, YM, NT, HS, YS, NO, JT, AM, TY, RCNM,

673 SU

674 Visualization: YM, YM

675 Funding acquisition: SU, MT, YK, TY, KA, IM, RCNM

676 Project administration: SU

677 Supervision: TH, KA, PFW, SU

678 Writing – original draft: YM, YN, MF, SU

679 Writing – review & editing: IM, MJ, TY, RCNM, PFW

680

681 **Competing interests:**

682 SU received grants and personal fees from AstraZeneca, GlaxoSmithKline, Sanofi, and grants

683 from Novartis, VIB, and Maruho Co. Ltd.

684 TY received honoraria from Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho and Kyorin

685 Pharma.

686 IM received honoraria from AstraZeneca, Sanofi, Shionogi, Japan Blood Products, Takeda, and  
687 Meiji pharma.

688 KA received honoraria from AstraZeneca, Boehringer Ingelheim Co., Ltd, GlaxoSmithKline plc.,  
689 Novartis Pharma, and Sanofi.

690 **Data and materials availability:**

691 All data are available in the main text or the supplementary materials.

692

693 **Figure legend**

694

695 **Fig. 1. Eosinophil-rich mucus from patients with ECRS showed high CT x-ray attenuation.**

696 (A) The microscopic appearance of sectioned mucus in patients with ECRS and non-ECRS  
697 (400×, hematoxylin-eosin staining, scale bar=50 μm). (B) Coronal sinus CT images of  
698 patients with ECRS (right) and non-ECRS (left). Red arrowheads indicate high CT  
699 attenuation areas in the maxillary sinus. (C) Macroscopic images of surgically-obtained  
700 sinus mucus from patients with ECRS and non-ECRS. (D) Comparison of mucus CT  
701 values between ECRS and non-ECRS groups (ECRS: n=40; non-ECRS: n=26, mean ± SD,  
702 \*\*p<0.01, Welch's *t* test).

703

704

705 **Fig. 2. Biophysical properties of mucus and their associations with CT density. (A)**

706 Measurement of dynamic viscosity against the shear rate of mucus samples using a

707 rotational viscometer. **(B)** The change in shear viscosity according to the shear rate (orange

708 line: ECRS, n=27; blue line: non-ECRS, n=15). **(C)** Correlation between shear viscosity at

709 a shear rate of  $10 \text{ s}^{-1}$  and the CT values of each sample (orange: ECRS, n=37; blue:

710 non-ECRS, n=25). Coefficient of correlation,  $R^2 = 0.45$  **(D)** Measurement of dry weight

711 of the mucus using a thermogravimetric analyzer (TGA). **(E)** The weight reduction rate of

712 the sample measured using TGA. Samples were gradually heated from 0 to 7.5 minutes and

713 then kept at  $100^\circ\text{C}$ . Lines and colored areas indicate mean and  $\pm \text{SD}$ , respectively (orange:

714 ECRS, n=4; blue: non-ECRS, n=6). **(F)** Correlation between dry weight and CT values

715 (orange: ECRS, n=4; blue: non-ECRS, n=6). Coefficient of correlation,  $R^2 = 0.69$  **(G)**

716 Measurement of the contact angle ( $\theta$ ) between water and mucus surface. **(H)** Comparison

717 of contact angle (orange: ECRS, n=40; blue: non-ECRS, n=27, \*\*\*\*p<0.0001,

718 Mann-Whitney U test). **(I)** Scatter plot shows correlation between contact angle and CT

719 values of the samples (orange: ECRS, n=40; blue: non-ECRS, n=27). Coefficient of

720 correlation,  $R^2 = 0.15$ .

721

722

723

724 **Fig. 3. Eosinophil- and neutrophil-specific protein contents in mucus.** The concentrations of

725 (A) galectin-10, (B) eosinophil-derived neurotoxin (EDN), and (C) myeloperoxidase

726 (MPO) in mucus from patients with ECRS and non-ECRS (ECRS, n=37; non-ECRS,

727 n=25; mean  $\pm$  SE, \* p<0.05 \*\* p<0.01 \*\*\* p<0.001, Welch's *t* test.).

728

729

730 **Fig. 4. The characteristics of cell aggregates.** (A) Preparation of aggEETs and aggNETs.

731 Isolated human eosinophils and neutrophils were stimulated with PMA to induce ETosis.

732 After plate shaking, aggregated cells were collected. (B) Macroscopic images of aggEETs

733 and aggNETs. (C) Microscopic appearance of sectioned aggEETs and aggNETs (400×,

734 hematoxylin-eosin staining, scale bar: 50 μm). (D) Comparison of CT values between

735 aggEETs and aggNETs (n=3, repeated measures, Welch's test, \*\*\*\*p<0.0001). (E) The

736 change in shear viscosity of cell aggregates according to shear rate (orange line: aggEETs,

737 n=3; blue line: aggNETs, n=3). (F) Mass reduction rate of cell aggregates using TGA

738 (orange: aggEETs, n=6; blue: aggNETs, n=6). Lines and colored area indicate mean and ±

739 SD, respectively. (G) Comparison of dry weights (aggEETs, n=6; aggNETs, n=6; \*p<0.05,

740 Welch's test). (H) Comparison of contact angles (aggEETs, n=14; aggNETs, n=14;

741 \*\*\*\*p<0.0001, Welch's test).

742

743



744

745 **Fig. 5. The effect of heparin and DNase on EETs.** (A) Scanning electron microscope (SEM)

746 images of non-treated control and heparin treated EETs (Scale bar=1  $\mu$ m). The EETs

747 consist of smooth stretch and globular domains (red arrowheads). (B) Transmission

748 electron microscope images of non-treated or heparin treated EETs. White arrowheads

749 indicate globular domain. (C) Comparison of fiber diameters of extracellular traps assessed

750 by SEM (n=200, \*\*\*\*p<0.0001, Welch's *t* test). (D) Measurement of free dsDNA detected

751 in the culture supernatant briefly treated with heparin and/or DNase 1 (n=4, \*\*\*\*p<0.0001,

752 Tukey's multiple comparisons test).

753

754

755 **Fig. 6. Heparin enhances the effect of DNase on aggEETs.** (A) Morphological change in  
756 aggEETs under the effect of DNase and/or heparin was assessed by SYTOX DNA dye  
757 using inverted fluorescence microscopy (scale bar=200  $\mu\text{m}$ ,  $\times 20$  objective). (B) The cell  
758 aggregates were treated with DNase and/or heparin for 2 hours and shear viscosity was  
759 assessed by a rotational rheometer (n=3 for each group, mean  $\pm$  SD). (C) Comparison of  
760 contact angle of cell aggregates treated with DNase and/or heparin (n=3, \*p<0.05,  
761 \*\*p<0.01, \*\*\*p<0.001, Kruskal-Wallis test: p<0.01).

762

763

764 **Fig. 7. The effect of heparin on mucus in patients with ECRS. (A)** The change in shear  
765 viscosity of mucus obtained from patients with ECRS (n=7 for each group, mean  $\pm$  SD).  
766 **(B)** Comparison of contact angle of mucus treated with DNase and/or heparin (each group:  
767 n=4, \*\*\*\*p<0.0001, Kruskal-Wallis test: p<0.01). **(C)** Illustration of the effects of heparin  
768 on aggEETs in mucus. Airway mucus contains large amounts of aggEETs that contribute  
769 to viscosity. Heparin relaxed their condensed chromatin structure and enhanced the effect  
770 of DNase.

771

	<b>Galectin-10</b>	<b>EDN</b>	<b>MPO</b>
<b>Shear viscosity</b>	$r = 0.74^*$	$r = 0.48^*$	$r = -0.25$
<b>Dry weight</b>	$r = 0.74^*$	$r = 0.25$	$r = -0.10$
<b>Contact angle</b>	$r = 0.58^*$	$r = 0.37^*$	$r = -0.28^*$
<b>CT value</b>	$r = 0.49^{**}$	$r = 0.25^*$	$r = 0.21^*$

772 **Table 1. Correlations between eosinophil- or neutrophil-specific proteins in mucus and its**  
773 **biophysical properties. \*p<0.05 \*\*\*p<0.001, Spearman's rank correlation coefficient**  
774

Figure 1





Figure 2





Figure 3



**Table 1. Correlation between eosinophil-specific proteins and physical properties**

	Correlation coefficients		
	galectin-10	EDN	MPO
shear viscosity	<b>r=0.74 *</b>	<b>r=0.48 *</b>	<b>r=-0.23</b>
dry weight	<b>r=0.74 *</b>	<b>r=0.25</b>	<b>r=-0.10</b>
contact angle	<b>r=0.58 *</b>	<b>r=0.37 *</b>	<b>r=-0.28 *</b>
CT value	<b>r=0.49 ***</b>	<b>r=0.25 *</b>	<b>r=0.21</b>



Figure 4




Figure 5




Figure 6




Figure 7

